drugset / Trial / NCT06808815
A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque Psoriasis
Phase 1
Completed
104 enrolled
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment
Summary
The main purpose of this study is to learn more about the safety and side effects of DC-806 when given by mouth to healthy participants and participants with Chronic Plaque Psoriasis. The study will have three parts. Each participant will enroll in only one part. For each participant, Part 1 will last up to 14 weeks, Part 2 will last up to 12 weeks, Part 3 will last up to 11 weeks including screening and follow-up.
Timeline
- Start
- 2021-09-22
- Primary completion
- 2022-08-23
- Completion
- 2022-08-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DC-806 | Unknown | — | Oral |